Immersive Decisionmaking for Biopharma Businesspeople.

A 3 day executive experience at the intersection of Agentic AI, genomics, and real-world data - designed for capitol allocators responsible for portfolio, pipeline, and performance.

Become a Founding Partner

Inquire About Sponsorship

Designed for Leaders Responsible for Outcomes

6,000+ c-suite attendees controlling
$1 Trillion+ in annual spend

Know What's Possible

Genome Unveiled exists to show how these decisions can be made tomorrow, not how they are made today.

Trial Rescue

Identify failing trials before they fail and intervene while there is still time.

See how one rescue can avert $500M–$3B in wasted investment.

Portfolio Prioritization

Gain the clarity to optimize ROI and P&L growth across complex platforms.

Reallocate capital, resources, and focus with clarity and confidence.

Phase IV Market Expansion

Unlock growth opportunities hidden in real-world patient data.

Visualize how label expansions can add $10B–$100B+ in lifetime value.

Genome Unveiled Leadership

Extensive experience-led growth across healthcare & events

Kirk Brote

Chief Executive Officer

Stu Heilsberg

Chief Strategy Officer

Carl Wooten

Chief Commercial Officer

Edward Farmer

Chief Communication Officer

Months of Learning in Hours

Healthcare data has outpaced executive understanding. At the same time Genomics, AI, and multi-omics, are reshaping portfolios faster than leaders can synthesize. Today’s conferences fragment information into panels and PowerPoints or speak to topics far downstream from executive decision-making. The result is that executives lack a shared, intuitive mental model to make platform-level decisions.

Genome Unveiled is an immersive executive platform where leaders in pharma, biotech, and AI learn how to use agentic AI to make better, faster decisions using real-world data, genomics, and advanced analytics. Through cinematic storytelling and curated executive experiences, it transforms complex science into actionable strategies for billion-dollar impact.

Founding Partners Are Now Being Selected

We are working with a small number of category-defining organizations across AI, genomics, and infrastructure to shape the inaugural experience.